Journal of Peking University(Health Sciences) ›› 2017, Vol. 49 ›› Issue (2): 295-302. doi: 10.3969/j.issn.1671-167X.2017.02.020

• Article • Previous Articles     Next Articles

Urothelial carcinoma-associated 1 enhances tamoxifen resistance in breast cancer cells through competitively inhibiting miR-18a

LI Xiu-nan△, LIU Ai-hui, TANG Xin, REN Yu   

  1. (Department of Breast Surgery, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China)
  • Online:2017-04-18 Published:2017-04-18
  • Contact: LI Xiu-nan E-mail:xiunan830@163.com
  • Supported by:

    Supported by Beijing Natural Science Foundation (7142055)

Abstract:

Objective: To investigate how urothelial carcinoma-associated 1 (UCA1) and miR-18a modulates acquired tamoxifen resistance and the relevant mechanisms in estrogen receptor (ER) positive cancer cells. Methods: qRT-PCR was performed to detect UCA1 and miR-18a expression in breast cancer cells. Dual luciferase assay was performed to detect the binding between miR-18a and UCA1 3′UTR. Tamoxifen sensitive MCF-7 cells were transfected with UCA1 expression vector or miR-18a inhi-bitors. Tamoxifen resistant LCC9 and BT474 cells were transfected with UCA1 siRNA or miR-18a mi-mics. CCK-8 assay was performed to detect cell viability. Soft agar assay was performed to assess cell colony formation. Flow cytometric analysis was performed to check cell cycle distribution. Results: UCA1 was significantly upregulated in tamoxifen resistant LCC2, LCC9, and BT474 cells than in tamoxifen sensitive MCF-7 cells. UCA1 expression was significantly upregulated in MCF-7 cells after treatment with 0.1 μmol/L tamoxifen. UCA1 overexpression enhanced cell viability of MCF-7 cells after tamoxifen treatment, while UCA1 siRNA significantly suppressed viability of LCC9 and BT474 cells after tamoxifen treatment. In MCF-7 cells, compared with vector control+tamoxifen group, the average cell colony number and colony size of the UCA1+tamoxifen group was 19.0% more and 29.0% larger respectively, while the proportions of the cells in G1 phase and in S phase were 7.3% lower and 6.7% higher respectively. In BT474 cells, compared with siRNA control+tamoxifen group, the average cell colony number and colony size of the si-UCA1+tamoxifen group were 54.0% less and 42.0% smaller respectively, while the proportions of the cells in G1 phase and in S phase were 9.0% higher and 6.2% lower respectively. UCA1 directly interacted with miR18a and reduced its expression in ER positive breast cancer cells. Knockdown of miR-18a increased viability of MCF-7 cells after tamoxifen treatment, while miR-18a overexpression significantly reduced viability of BT474 cells after tamoxifen treatment. In MCF-7 cells, compared with miRNA inhibitor control+tamoxifen group, the average cell colony number and colony size of the miR-18a inhibitor+tamoxifen group were 15.0% more and 33.0% larger respectively, while the proportions of the cells in G1 phase and in S phase were 8.8% lower and 5.3% higher respectively. In BT474 cells, compared with miRNA control+tamoxifen group, the average cell colony number and colony size of the miR-18a mimics+tamoxifen group were 47.0% less and 25.0% smaller respectively, while the proportions of the cells in G1 phase and in S phase were 13.3% higher and 7.9% lower respectively. Conclusion: UCA1 can increase tamoxifen resistance of ER positive breast cancer cells via competitively inhibiting of miR18a.

Key words: Receptors, estrogen, Breast neoplasms, UCA1, Tamoxifen

CLC Number: 

  • R737.9
[1] Jian-xun MA,You-chen XIA,Bi LI,Hong-mei ZHAO,Yu-tao LEI,Xi BU. Choice of immediate breast reconstructive methods after modified radical mastectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 612-618.
[2] Yun-jing ZHANG,Li-ying QIAO,Meng QI,Ying YAN,Wei-wei KANG,Guo-zhen LIU,Ming-yuan WANG,Yun-feng XI,Sheng-feng WANG. Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 471-479.
[3] Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.
[4] Guo-hong SONG,Hui-ping LI,Li-jun DI,Ying YAN,Han-fang JIANG,Ling XU,Dong-gui WAN,Ying LI,Mo-pei WANG,Yu XIAO,Ru-yan ZHANG,Ran RAN,Huan WANG. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 254-260.
[5] KANG Lei, HUO Yan, WANG Rong-fu, ZHANG Chun-li, YAN Ping, XU Xiao-jie. In vivo imaging of breast tumors by a 99mTc radiolabeled probe targeting microRNA-155 in mice models [J]. Journal of Peking University(Health Sciences), 2018, 50(2): 326-330.
[6] ZHU Yan,SHI Yong-jin,ZHAO Yu-liang, ZHU Ping. Topoisomerase inhibitor upregulates MICA/B expression in breast cancer cells through ATM/ATR and NF-κB pathway [J]. Journal of Peking University(Health Sciences), 2018, 50(2): 318-325.
[7] SHAO Bin, LI Hui-ping, DI Li-jun, SONG Guo-hong, JIANG Han-fang, LIANG Xu, WANG Chao-ying, YAN Ying, LIN Xiao-lin, WANG Li-na, WAN Feng-ling, YUAN Yan-hua, YOU Miao-ning. Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer [J]. Journal of Peking University(Health Sciences), 2016, 48(2): 304-309.
[8] ZHANG Shuang, WANG Ying, GUO Zheng-Min, ZHANG Hong, XU Ling, LIU Yin-Hua, LI Ting. Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome 17 centromere locus [J]. Journal of Peking University(Health Sciences), 2014, 46(5): 686-690.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!